Development of sulphonamide-trimethoprim combinations for urinary tract infections. Part 2: Comparative pharmacokinetics of five sulphonamides.
The pharmacokinetics and renal excretion of the sulphonamides sulphachloropyridazine, sulphadiazine, sulphaisodimidine, sulphamerazine, and sulphamethoxazole were investigated in a cross-over study with doses of 800 mg each. The serum half-life, urine levels, distribution volume, protein binding and potential antibacterial activity in the urine renders sulphadiazine the preferred component in a combination tablet together with trimethoprim for the treatment of urinary tract infections.
D000328:Adult; D004338:Drug Combinations; D005260:Female; D006207:Half-Life; D006801:Humans; D007700:Kinetics; D013410:Sulfachlorpyridazine / Q000494:pharmacology; D013411:Sulfadiazine / Q000494:pharmacology; D013416:Sulfamerazine / Q000494:pharmacology; D013418:Sulfamethazine / Q000494:pharmacology; D013420:Sulfamethoxazole / Q000494:pharmacology; D013449:Sulfonamides / Q000494:pharmacology* / Q000652:urine; D014295:Trimethoprim / Q000494:pharmacology*; D014552:Urinary Tract Infections / Q000188:drug therapy*
D004338:Drug Combinations; D013449:Sulfonamides; D013411:Sulfadiazine; D013418:Sulfamethazine; D014295:Trimethoprim; D013420:Sulfamethoxazole; D013410:Sulfachlorpyridazine; D013416:Sulfamerazine